Supernus Pharmaceuticals | Spese Di Vendita E Di Amministrazione



Selling And Administration Expenses Cambiamento Data
Abbott USD 2.91B 21M 2024-12
ANI Pharmaceuticals USD 69.72M 9.36M 2024-12
Aurora Cannabis CAD 38.18M 2.05M 2024-12
Bristol-Myers Squibb USD 2.1B 129M 2024-12
Canopy Growth CAD 40.62M 308K 2024-12
Corcept Therapeutics USD 83.37M 9.63M 2024-12
Eisai JPY 104.52B 7.1B 2024-12
Eli Lilly USD 2.42B 324.7M 2024-12
Indivior 133M 11M 2024-09
Novo Nordisk 16.59B 501M 2024-09
Pacira USD 79.61M 5.28M 2024-12
Perrigo USD 234.8M 36.7M 2024-12
Pfizer USD 4.27B 1.06B 2024-12
Supernus Pharmaceuticals USD 79.41M 9.66M 2024-12
United Therapeutics USD 162.5M 8.4M 2024-12
Xeris Pharmaceuticals USD 80.28M 35.31M 2024-12



Supernus Pharmaceuticals Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2025.